Birk Venture invests in Nextera AS. Nextera is a biotechnology
company based on a proprietary new phage display technology. The
company develops pharmaceuticals targeting autoimmune diseases
through unique new drug targets. Within five years, Nextera has the
vision to be one of Europe´s five leading sources of new drug targets
and drug candidates for autoimmune diseases. With this investment
Birk Venture makes a new important engagement in the development
of new medicines. Birk Venture takes two board positions in the
company.
